Chinese Journal of Antituberculosis ›› 2020, Vol. 42 ›› Issue (4): 391-397.doi: 10.3969/j.issn.1000-6621.2020.04.017
• Original Articles • Previous Articles Next Articles
FAN Xin-xin,WU Di,LIN You-fei,CHEN Xiao-hong()
Received:
2019-12-22
Online:
2020-04-10
Published:
2020-04-07
Contact:
Xiao-hong CHEN
E-mail:cxhong6886@126.com
FAN Xin-xin,WU Di,LIN You-fei,CHEN Xiao-hong. Disseminated tuberculosis induced by adalimumab in the treatment of ankylosing spondylitis: one case report and literature review[J]. Chinese Journal of Antituberculosis, 2020, 42(4): 391-397. doi: 10.3969/j.issn.1000-6621.2020.04.017
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2020.04.017
序号 及文献 编号 | 年龄 (岁) | 性 别 | 临床症状 | 临床体征 | 结核 病接 触史 | 结核 病治 疗史 | 基础 疾病 | 治疗前 结核病 筛查 | 结核病 灶分布 部位 | 诊断依据 | 抗结核治疗药品 | 转归 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
例1[2] | 62 | 女 | 发热 | 无 | 不明 | 不明 | 类风 湿性 关节炎 | 不明 | 肺、肝 | 肝活检组织培养 | 异烟肼、乙胺丁醇、吡嗪酰胺 | 好转 |
例2[3] | 65 | 女 | 反复发热,呼吸困难6个月 | 消瘦,指间关节畸形,双下肺叩诊浊音 | 有 | 无 | 类风 湿性 关节炎 | 不明 | 肺、腹腔 | 特异性影像学征象及痰涂片阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇、左氧氟沙星 | 好转 |
例3[4] | 72 | 女 | 咳嗽、发热 | 腹膨隆 | 无 | 无 | 类风 湿性 关节炎 | 不明 | 肺、腹 腔、脾 | 特异性影像学征象及痰液、腹腔积液结核分枝杆菌培养阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇 | 恶化 |
例4[5] | 75 | 女 | 发热、右上颌疼痛 | 不明 | 有 | 预防性 抗结核 治疗 | SAPHO 综合征 | 无 | 肺、胃 | 特异性影像学征象及胃液结核分枝杆菌培养阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇 | 死亡 |
例5[6] | 61 | 男 | 发热、咳嗽和呼吸困难2周 | 全身皮肤多发红斑 | 无 | 无 | 银屑病 | 无 | 肺、 淋巴结 | 特异性影像学征象及基因检测阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇 | 好转 |
例6[7] | 9 | 女 | 发热、左腹股沟淋巴结炎、左膝关节炎 | 膝关节疼痛 | 有 | 有 | 幼年 特发性 关节炎 | 结核 感染 | 肺、支气 管、胸膜、 脑、淋巴 结、膝 | 活检、特异性影像学征象、基因检测及培养阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇 | 好转 |
例7[8] | 17 | 女 | 呼吸困难、嗜睡 | 颈轻度强直、阵发性肌肉痉挛 | 无 | 无 | SAPHO 综合征 | 无 | 肺、支气 管、胸膜、 腹腔、脑 | 特异性影像学征象、基因检测及活检阳性 | 异烟肼、利福平、吡嗪酰胺、乙胺丁醇、左氧氟沙星(莫西沙星)、链霉素 | 恶化 |
例8[9] | 老年 患者 (具体 不详) | 男 | 咽炎 | 不明 | 不明 | 不明 | 银屑病、 关节炎 | 不明 | 不明 | 不明 | 不明 | 不明 |
[1] | Wang JY, Hsueh PR, Wang SK , et al. Disseminated tuberculosis: a 10-year experience in a medical center. Medicine (Baltimore), 2007,86(1):39-46. |
[2] | Pednekar M, Chandra AB, Chandra PA . Disseminated tuberculosis secondary to adalimumab. Am J Ther, 2012,19(4):e139-40. |
[3] | Muñoz-Oca JE, Villarreal Morales ML, Nieves-Rodriguez A , et al. Concomitant disseminated histoplasmosis and disseminated tuberculosis after tumor necrosis factor inhibitor treatment: a case report. BMC Infect Dis, 2017,17(1):70. |
[4] | Dantes E, Tofolean DE, Fildan AP , et al. Lethal disseminated tuberculosis in patients under biological treatment-two clinical cases and a short review. J Int Med Res, 2018,46(7):2961-2969. |
[5] | Watanabe S, Kaneko Y, Kawamoto H , et al. Paradoxical response with increased tumor necrosis factor-α levels to anti-tuberculosis treatment in a patient with disseminated tuberculosis. Respir Med Case Rep, 2017,20:201-204. |
[6] | Bae JY, Lee JI, Kim HL , et al. Disseminated tuberculosis following adalimumab treatment in psoriasis despite negative screening. Int J Dermatol, 2019,58(1):98-100. |
[7] | Guerrero-Laleona C, Calzada-Hernández J, Bustillo-Alonso M , et al. Disseminated tuberculosis resulting from reinfection in a pediatric patient sequentially treated with etanercept and adalimumab. Pediatr Infect Dis J, 2017,36(1):109-110. |
[8] | Hess S, Hospach T, Nossal R , et al. Life-threatening disseminated tuberculosis as a complication of TNF-α blockade in an adolescent. Eur J Pediatr, 2011,170(10):1337-1342. |
[9] | Patel S, Weaver MD, Roy S. Miliary tuberculosis and herpes pharyngitis after a trip to a developing country: dangers of biologics. BMJ Case Rep, 2018, 2018. pii: bcr-2018-224459. |
[10] | 谢玉婷, 汪年松 . 阿达木单抗在类风湿关节炎治疗中的应用. 世界临床药物, 2012,33(2):65-69. |
[11] | 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家建议组. 肿瘤坏死因子拮抗剂应用中结核病预防与管理专家共识. 中华风湿病学杂志, 2013,17(8):508-512. |
[12] | Brassard P, Lowe AM, Bernatsky S , et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum, 2009,61(3):300-304. |
[13] | Seong SS, Choi CB, Woo JH , et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol, 2007,34(4):706-711. |
[14] | Carmona L, Hernández-García C, Vadillo C , et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol, 2003,30(7):1436-1439. |
[15] | Gómez-Reino JJ, Carmona L, Valverde VR , et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum, 2003,48(8):2122-2127. |
[16] | Pyo J, Cho SK, Kim D , et al. Systemic review: agreement between the latent tuberculosis screening tests among patients with rheumatic diseases. Korean J Intern Med, 2018,33(6):1241-1251. |
[17] | 全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508. |
[18] | Mandic' D, Curcic' R, Radosavljevic' G . et al. Recommendations for tuberculosis screening before and during treatment with tumour necrosis factor inhibitors. Srp Arh Celok Lek, 2009,137(3/4):211-216. |
[19] | Wallis RS, van Vuuren C, Potgieter S . Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis, 2009,48(10):1429-1432. |
[1] | Tuberculosis Control Branch of Chinese Antituberculosis Association, The Youth Branch of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Evidence-based guidelines for application of digital adherence technology in tuberculosis medication management in China [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 385-397. |
[2] | Li Jinhao, Hu Dongmei, Xu Caihong. Investigation on the willingness of tuberculosis health-care workers to implement tuberculosis preventive treatment and analysis of influencing factors [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 398-407. |
[3] | Li Yuhong, Mei Jinzhou, Su Wei, Ruan Yunzhou, Liu Yushu, Zhao Yanlin, Liu Xiaoqiu. Analysis of the treatment outcomes and influencing factors of rifampicin-resistant pulmonary tuberculosis patients aged 65 and above in China from 2015 to 2021 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 408-415. |
[4] | Jiang Xue, Bai Yunlong, Ma Jianjun, An Yuan, Yang Fan, Zhao Qinglong. Status and influencing factors of diagnosis and treatment delay of rifampicin resistant pulmonary tuberculosis patients, Jilin Province, 2020—2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 416-424. |
[5] | Wu Xuan, Zhang Yanqiu, Xu Jiying, Meng Dan, Sun Dingyong. Analysis of factors influencing the treatment outcomes of patients with pulmonary tuberculosis and diabetes mellitus in Henan Province (2019—2023) [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 425-431. |
[6] | An Yuan, Bai Yunlong, Zhao Qinglong, Ma Jianjun, Jiang Xue, Pan Yan, Gao Ying, Gao Zhihui. Analysis of treatment outcomes and influencing factors of patients with pulmonary tuberculosis complicated with diabetes mellitus in Jilin Province,2018—2022 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 432-438. |
[7] | Feng Wei, Zheng Hailun, Meng Weili, Luo Ping. Analysis of under-reporting before arrival of pulmonary tuberculosis patients registered and managed by Tuberculosis Prevention and Control Institutions in Xicheng District, Beijing from 2018 to 2023 [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 439-443. |
[8] | Hu Yifan, Du Boping, Wu Yadong, Zhu Chuanzhi, Zhang Lanyue, Jia Hongyan, Sun Qi, Pan Liping, Zhang Zongde, Li Zihui. Experimental study on the role of Mce4C in the uptake and utilization of cholesterol by Mycobacterium tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 444-453. |
[9] | Sheng Jie, Hong Kaifeng, Mierzhati Aisha, Tang Wei, Dilixiati Abulizi. Study on the mechanism of IL-22 and p38 MAPK signaling pathways in inhibiting bone destruction in bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 454-459. |
[10] | Wang Yingchao, Liu Weiyi, Ji Xiuxiu, Shang Xuetian, Jia Hongyan, Zhang Lanyue, Sun Qi, Du Boping, Zhu Chuanzhi, Pan Liping, Zhang Zongde. Profile analysis of circRNA expression and identification of diagnostic markers in peripheral blood mononuclear cells of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 460-470. |
[11] | Zhu Mingzhi, Shao Yanqin, Fan Dapeng, Liu Libin, Mei Bin, Dai Lingshan, Cai Long. Diagnostic value of urine lipoarabinomannan antigen detection in extrapulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 471-476. |
[12] | Hao Mingxiao, Mi Jie, Xu Zongyi. Effectiveness of a continuity of care model in patients with tuberculous meningitis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 477-481. |
[13] | Shang Xiyu, Zhang Huifang, Cao Yuqing, Xiong Yibai, Ji Xinyu, Tian Yaxin, Li Jiajia, Wang Ni, Ma Yan. Bibliometric analysis of global research status and hotspots in the basic research of Traditional Chinese Medicine for tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 482-497. |
[14] | Qin Lili, Yang Chengqing, Mai Hongzhen, Xu Qifeng, Xue Xinying, Lu Xiwei. Advances in the clinical diagnosis and treatment of post-tuberculosis chronic pulmonary aspergillosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 498-504. |
[15] | Luo Li, Luo Linzi, Yin Quhua, Zhou Lei, Lu Zhibin, Ding Yan, Xiao Yangbao. Progress in bronchoscopic diagnosis and treatment of lymph node fistula tracheobronchial tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(4): 505-512. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||